(VIANEWS) – ORPEA (ORP.PA) experienced a drastic drop in its stock price over five trading sessions from EUR0.01 to EUR0.001, contributing to overall bearish sentiment in the market. CAC 40 index (which ORPEA belongs) shows an uptick by 0.61% to reach EUR7,671.82, reflecting ORPEA’s downward trajectory from previous sessions.
ORPEA’s recent performance has resulted in its stock price plummeting 98.58% below its 52-week high of EUR0.88, an alarming development for investors hoping for continued growth. Analysts are closely tracking this situation and will likely provide further insights into why its stock has plummeted so drastically.
Key Figures:,, Key figures include ORPEA (ORP.PA) as a ticker and CAC 40 index as an index; 52 week high was EUR0.88 and last close was EUR0.01, current price being EUR0.001, market trend being bearish and so forth.
About ORPEA
ORPEA SA is a healthcare provider specializing in nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, psychiatric hospitals and home care services with presence across 20 countries. Their personalized care services include accommodation, meals, laundry and specialized workshops as well as their post-acute and rehabilitation hospitals providing treatment for various physical conditions while their psychiatric hospitals treat various mental disorders. Furthermore, ORPEA SA also provides home care services including housekeeping, daily life assistance, movement assistance. Founded in 1989 with headquarters located in Puteaux France
Yearly Analysis
ORPEA’s current stock price of EUR0.01 is significantly below its 52-week low of EUR0.01, suggesting it may have hit bottom. ORPEA anticipates sales growth of 6.3% for this year and 6.2% next year – this would suggest revenue is expected to increase in coming years; however, investors should conduct further research prior to making any definitive investment decisions.
Technical Analysis
ORPEA stock has seen its value fall significantly below both its 50-day and 200-day moving averages, and trading volume of 134,681,335 indicates reduced buying interest.
Over the past week, this stock has shown an intraday variation average of negative 3.10%, suggesting an upward trend. This echoes its monthly and quarterly averages, where negative 0.79% and positive 5.49% values were respectively observed.
The stochastic oscillator, an indicator for overbought and oversold conditions, has classified ORPEA’s stock as being overbought (>=80), signalling that its price may require some form of correction or consolidation period.
Due to current market conditions and an overbought status of stocks, investors would be prudent to exercise extreme caution before making any definitive investment decisions.
Quarter Analysis
Sales GrowthORPEA’s current sales growth stands at 6.3% and it is anticipated that it will remain at this rate over time, signaling steady increases in revenues for the company.
Revenue GrowthORPEA’s year-on-year quarterly revenue growth has jumped 10.7% year over year to 4.93B for twelve trailing months – this indicates that their business is expanding and performing financially well.
Equity Analysis
Earnings Per Share (EPS) is a key financial metric used to gauge how profitable a company is per outstanding share. ORPEA currently stands with an EPS value of EUR-4.11 over the past twelve months indicating it experienced losses amounting to EUR4.11 per share over that timeframe.
Return on Equity (ROE) is an essential financial ratio that measures a company’s profitability relative to the amount of shareholder equity it holds. ORPEA currently boasts an ROE for the trailing twelve months that stands at negative -445.48%, meaning it incurred losses totalling EUR445.48 for every EUR100 of shareholder equity over this time.
Investors should keep in mind that negative EPS and ROE figures indicate a company has not been profitable in the previous year, providing valuable information about future returns on their investment in ORPEA. While this data can provide useful insight, investors should also take into account other aspects of their company such as its financial health, growth prospects and industry outlook when making any decisions about investments in ORPEA.
More news about ORPEA (ORP.PA).
